Eleven biomarkers most doctors miss.

The annual physical was built for a different century.

Standard blood work catches diabetes once it has arrived, cholesterol once it is elevated, and cancer once it is often already established. It was never designed to catch the eleven-year runway before disease presents. Dr Oliver Zolman's clinical writing sets out, test by test, the screens that routinely fall outside a standard GP panel or annual check-up — not because they are experimental, but because most primary care systems were never built around a screening calendar this granular.

This is one of the reasons a longevity-focused assessment differs so sharply from a routine physical: it is organised around what is guideline-recommended but rarely ordered, rather than around what is easy to bill. The eleven tests below span cardiovascular risk, body composition, fitness, airway and sleep, blood pressure, and cancer screening. None of them are exotic. All of them are testable today, in most health systems, by name.

The clinical reasoning behind including each one is the same: it closes a gap between what a symptom-based system checks and what a risk-based, decades-ahead system should check.

The cholesterol test almost nobody orders.

Lipoprotein(a), or Lp(a), is arguably the single most consequential blood test missing from routine cardiovascular screening. It is roughly 90% genetically determined — set largely by inheritance rather than diet or exercise — and it is estimated to be around six times more atherogenic than LDL cholesterol on a particle-for-particle basis. Crucially, it does not move meaningfully with statins or lifestyle change, which is exactly why it goes undetected: a clinician who checks only a standard lipid panel and sees normal LDL has no way of knowing an elevated Lp(a) is quietly driving risk underneath it.

Until recently there was little to offer a patient with high Lp(a) beyond risk-factor management elsewhere. That has changed. Evolocumab, a PCSK9 inhibitor already in cardiovascular use, lowers Lp(a) by roughly 20%. More significantly, pelacarsen — an antisense therapy specifically targeting Lp(a) — is expected to reach approval around 2027 and has shown reductions of up to 90% in trial data. Because Lp(a) is largely fixed for life once measured, and because emerging therapy is now catching up to the diagnosis, universal one-time screening is now recommended by cardiology bodies in both the United States and the European Union. It is a single blood draw, done once, that changes risk stratification for the rest of a patient's life.

Where Lp(a) identifies genetic cardiovascular risk, CTCA with AI-enhanced imaging (coronary CT angiography) shows what that risk has actually done to the arteries. For people already assessed as high risk for heart disease, CTCA does something a calcium score alone cannot: it visualises soft, vulnerable plaque, inflamed plaque, lipid-rich plaque that is actively dying and destabilising, and calcified, stable plaque — each of which carries a different clinical implication. AI-assisted plaque analysis packages that quantify and characterise this material are now approved for clinical use in both the US and the EU, meaning the interpretation is no longer solely dependent on a radiologist's visual read. For the right patient, this is the difference between "your calcium score is zero, you're fine" and an accurate picture of what is actually building in the vessel wall.

The measurement that beats the scale.

Waist-to-hip ratio is a simple measurement that standard care rarely bothers to take, despite outperforming BMI as a marker of metabolic risk. The target is straightforward: waist circumference should be approximately 85% of hip circumference. The hip measurement should be taken at its widest point, including the glutes, since this is what makes the ratio meaningful as a proxy. A high WHR is a reasonable proxy for high visceral adipose tissue (VAT) — the inflammatory, metabolically active fat that surrounds the organs rather than sitting subcutaneously. This applies to both men and women, and it takes under a minute with a tape measure, which makes its absence from most check-ups a genuine missed opportunity rather than a resourcing problem.

Free testosterone is the other body-composition-adjacent test that standard panels get wrong by omission — specifically, by measuring total testosterone alone. Total testosterone without sex hormone-binding globulin (SHBG) run alongside it is close to clinically meaningless in ambiguous cases, because SHBG determines how much of that total is actually biologically available. Free testosterone, calculated from total testosterone and SHBG together, picks up genuine deficiency far more accurately than total testosterone in isolation — in men and in women. This matters for energy, body composition, mood, and cardiovascular risk profiling alike. Anyone starting or continuing testosterone therapy should also be monitored on PSA, haematocrit (Hct), and the testosterone-to-oestrogen (T/E) ratio, since these track the therapy's downstream effects that testosterone level alone will not show.

Cheaper than a VO2 max mask, and more useful.

The Bruce Treadmill test is old, inexpensive, and still one of the best fitness screens available — which is exactly why it is worth reviving rather than replacing. It measures cardiorespiratory fitness in METs (metabolic equivalents) across seven progressive stages, each three minutes long, with incline and speed increasing at every stage. The target is to reach the top dotted line on the age- and gender-adjusted reference chart for your stage — a visual, easily communicated benchmark rather than an abstract number. For most people, this test is cheaper to administer and more clinically actionable than a VO2 max test performed with a metabolic mask, despite VO2 max getting most of the current attention in longevity circles.

Alongside individual tests, Dr Zolman's site hosts a screening calculator — a tool that takes basic inputs and generates a personalised list of every guideline-recommended screening test relevant to that person, organised across imaging, device-based, and biosample categories. The value of a tool like this is structural: it replaces "what should I ask my doctor to check" with an actual, categorised checklist, which is precisely the gap that produces missed tests like the ten others in this essay.

Sleep apnoea your smartwatch cannot see.

Obstructive sleep apnoea (OSA) and upper airway resistance syndrome (UARS) sit upstream of cardiovascular disease, cognitive decline, and metabolic dysfunction, and they are routinely missed because consumer wearables are not built to detect them. WatchPAT and Nox-T3 are home sleep tests that actually can. The clinical targets are that both the respiratory disturbance index (RDI) and the apnoea-hypopnoea index (AHI) should sit under 5. WatchPAT ONE is a single-use device priced around $130 in the US and £250 in the UK. Nox-T3 is prescription-only, can be worn for up to seven nights, and costs upwards of $1,000 plus a roughly $300 consultation. Devices like Whoop, Oura, and Apple Watch — however good their sleep-stage tracking has become — cannot detect OSA or UARS to a diagnostic standard. This is a case where consumer wearable data creates false reassurance rather than genuine screening.

The clinical reasoning that ties this chain together is structural: a Cottle test is a thirty-second screen, a WatchPAT is a week at home, and CBCT is a single low-dose scan — and together they turn "possible sleep apnoea" into an actual anatomical diagnosis with a defined set of treatment options attached to it.

The reading your GP visit cannot capture.

A single blood pressure reading, taken in a clinic, at one moment in one day, is a poor proxy for a number that fluctuates constantly and matters most when nobody is measuring it. Hilo.com makes a medical-grade wearable blood pressure device priced around $200 / £200 for lifetime use — a one-time cost rather than a subscription — that reads blood pressure automatically every 15 minutes, 24 hours a day, including through sleep. That nighttime data is the clinically critical part: blood pressure should dip by roughly 10–20% during sleep, and a blunted or absent nocturnal dip is an independent marker of cardiovascular risk that a daytime clinic reading will never surface. The device should be calibrated monthly against a standard arm cuff to maintain accuracy. This is one of the reasons continuous blood pressure monitoring is increasingly addressed as a longevity-essential rather than a hypertension-only tool — the signal that matters is often the one that happens at 3am.

Standard mammography was not built for dense breast tissue.

Conventional 2D mammography has a known blind spot: it performs worse in women with dense breast tissue, a condition more common in women under 60 — precisely the population where earlier detection matters most for lifetime outcomes. Next-generation mammography addresses this directly. 3D digital breast tomosynthesis (DBT) reconstructs breast tissue in thin slices rather than a single flattened image, reducing the masking effect of dense tissue. AI-enhanced reading platforms — including Transpera, Deep Health, Lunit, and Vara — are now used alongside radiologist review to catch findings a human read alone may miss or to flag cases for closer attention. Contrast-enhanced mammography, using intravenous iodine contrast, is emerging as an alternative to MRI with gadolinium contrast for supplemental screening in higher-risk or dense-breast patients, without the cost and access barriers that MRI carries in many systems.

None of this replaces clinical judgment about who needs supplemental screening and how often. What it does is give clinicians tools that were simply not on the table a decade ago, for a population — women with dense breast tissue — that standard 2D mammography has never served particularly well.

Taken individually, each of these tests plugs a specific gap. Taken together, the clinical reasoning is the same one that runs through Dr Zolman's writing throughout: standard care screens for disease that has already declared itself, while a risk-based approach screens for the years of runway beforehand. Readers wanting the full teaching behind each of these tests — including diagnostic nuance, therapy selection, and case-by-case interpretation — should look to Dr Zolman's Longevity School curriculum at oliverzolman.com/longevity-school, which this essay draws from and summarises rather than replaces.

At Clinic82, tests of this kind are not an optional add-on to a check-up; they are routine components of our Assessments, and each result is integrated into the broader 82-organ mapping that underpins every protocol we build. Lp(a) and free testosterone inform the cardiovascular and endocrine organ scores; the airway chain and 24/7 blood pressure data feed the sleep and cardiovascular clocks directly; next-generation mammography and CTCA sit inside the cancer- and cardiovascular-risk components of the same framework. The goal is the same one this essay opened with — catching what a standard physical is not built to catch, systematically, and building the resulting intervention plan around it.